Prescient Therapeutics (FRA:UDD) EV-to-EBIT

Prescient Therapeutics Annual Data
	Trend	Jun13	Jun14	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23
EV-to-EBIT							-1.40	-4.24	-34.10	-17.44	-4.38

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT																-	-17.44	-	-4.38	-

For the Biotechnology subindustry, Prescient Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's EV-to-EBIT falls into.

Prescient Therapeutics EV-to-EBIT Calculation

Prescient Therapeutics's EV-to-EBIT for today is calculated as:

Prescient Therapeutics's current Enterprise Value is €71.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics  (FRA:UDD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Prescient Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Prescient Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was €0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (FRA:UDD) Business Description